BCYC Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 8.50%

Insider Buying (Last 12 Months): $21,229,062.72

Insider Selling (Last 12 Months): $683,852.68

Bicycle Therapeutics Insider Trading History Chart

Bicycle Therapeutics Share Price & Price History

^$14.68

▼ -0.32 (-2.13%)

As of 12/20/2024 06:31 PM ET

Days: 30 | 90 | 365

URGENT: This Altcoin Opportunity Won’t Wait – Act Now

From Crypto Swap Profits | Ad

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

Bicycle Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/16/2024	Bros. Advisors Lp Baker	Director	Buy	500,000	$15.34	$7,670,000.00	9,995,274
12/13/2024	Bros. Advisors Lp Baker	Director	Buy	985,397	$13.76	$13,559,062.72	9,537,643
11/11/2024	Travis Alvin Thompson	CAO	Sell	6,256	$25.11	$157,088.16	19,241
10/3/2024	Kevin Lee	CEO	Sell	3,212	$22.26	$71,499.12	380,864
10/3/2024	Michael Charles Ferguso Hannay	Insider	Sell	247	$22.26	$5,498.22	22,398
10/3/2024	Michael Skynner	CTO	Sell	972	$22.26	$21,636.72	92,945
10/3/2024	Travis Alvin Thompson	CAO	Sell	153	$22.26	$3,405.78	22,922
7/3/2024	Kevin Lee	CEO	Sell	3,194	$19.64	$62,730.16	384,076
7/3/2024	Michael Charles Ferguso Hannay	Insider	Sell	246	$19.64	$4,831.44	22,645
7/3/2024	Michael Skynner	CTO	Sell	967	$19.64	$18,991.88	93,917
7/3/2024	Travis Alvin Thompson	CAO	Sell	148	$19.64	$2,906.72	23,075
4/11/2024	Michael Charles Ferguso Hannay	Insider	Sell	257	$22.49	$5,779.93	22,891
4/3/2024	Kevin Lee	CEO	Sell	3,158	$23.81	$75,191.98	387,270
4/3/2024	Michael Skynner	CTO	Sell	955	$23.81	$22,738.55	94,884
4/3/2024	Nicholas Keen	Insider	Sell	790	$23.81	$18,809.90	62,803
4/3/2024	Travis Alvin Thompson	CAO	Sell	152	$23.81	$3,619.12	23,223
1/3/2024	Kevin Lee	CEO	Sell	8,703	$17.50	$152,302.50	390,428
1/3/2024	Nigel Crockett	Insider	Sell	2,643	$17.50	$46,252.50	48,716
1/3/2024	Travis Alvin Thompson	CAO	Sell	604	$17.50	$10,570.00	23,375
10/3/2023	Alistair Milnes	COO	Sell	442	$20.00	$8,840.00	36,839
10/3/2023	Kevin Lee	CEO	Sell	1,470	$20.00	$29,400.00	322,131
10/3/2023	Nicholas Keen	Insider	Sell	272	$20.00	$5,440.00	38,233
10/3/2023	Travis Alvin Thompson	CAO	Sell	54	$20.00	$1,080.00	7,979
7/3/2023	Kevin Lee	CEO	Sell	1,498	$25.10	$37,599.80	323,601
7/3/2023	Michael Skynner	CTO	Sell	451	$25.10	$11,320.10	70,924
7/3/2023	Nicholas Keen	Insider	Sell	336	$25.10	$8,433.60	38,505
7/3/2023	Travis Alvin Thompson	CAO	Sell	61	$25.10	$1,531.10	8,033
4/3/2023	Kevin Lee	CEO	Sell	1,486	$21.11	$31,369.46	325,099
4/3/2023	Lee Kalowski	CFO	Sell	376	$21.11	$7,937.36	30,309
4/3/2023	Michael Skynner	CTO	Sell	447	$21.11	$9,436.17	71,375
4/3/2023	Nicholas Keen	Insider	Sell	319	$21.11	$6,734.09	38,841
1/3/2023	Kevin Lee	CEO	Sell	6,000	$29.06	$174,360.00	326,585
1/3/2023	Lee Kalowski	CFO	Sell	1,815	$29.06	$52,743.90	30,685
1/3/2023	Nigel Crockett	Insider	Sell	1,801	$29.06	$52,337.06	30,699
12/21/2021	Pierre Legault	Director	Sell	44,537	$57.11	$2,543,508.07

URGENT: This Altcoin Opportunity Won’t Wait – Act Now

From Crypto Swap Profits | Ad

>> Register for the Workshop Now

SEC Filings (Institutional Ownership Changes) for Bicycle Therapeutics (NASDAQ:BCYC)

86.15% of Bicycle Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Bicycle Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
12/19/2024	Principal Financial Group Inc.	443,141	$10.03M	0.0%	N/A	0.642%
11/16/2024	Geode Capital Management LLC	38,335	$0.87M	0.0%	+79.3%	0.081%
11/15/2024	Jane Street Group LLC	20,180	$0.46M	0.0%	+35.7%	0.042%
11/15/2024	Wexford Capital LP	34,879	$0.79M	0.2%	-22.3%	0.073%
11/15/2024	State Street Corp	86,271	$1.95M	0.0%	+233.5%	0.181%
11/15/2024	Point72 Asset Management L.P.	899,799	$20.36M	0.1%	+1,438.1%	1.892%
11/15/2024	Parkman Healthcare Partners LLC	445,396	$10.08M	1.3%	-16.8%	0.937%
11/15/2024	HighVista Strategies LLC	139,544	$3.16M	1.1%	+9.7%	0.293%
11/15/2024	Erste Asset Management GmbH	14,000	$0.33M	0.0%	N/A	0.029%
11/14/2024	Verition Fund Management LLC	212,151	$4.80M	0.0%	-20.5%	0.446%
11/14/2024	Tybourne Capital Management HK Ltd.	1,394,535	$31.56M	8.8%	-7.6%	2.933%
11/13/2024	FMR LLC	150,516	$3.41M	0.0%	N/A	0.317%
11/13/2024	The Manufacturers Life Insurance Company	129,705	$2.94M	0.0%	+33.2%	0.273%
11/13/2024	Horizon Kinetics Asset Management LLC	13,792	$0.31M	0.0%	-4.2%	0.029%
11/12/2024	Westfield Capital Management Co. LP	1,850,945	$41.89M	0.2%	+21.5%	3.897%
11/12/2024	L & S Advisors Inc	59,735	$1.35M	0.1%	+2.4%	0.126%
11/8/2024	BNP PARIBAS ASSET MANAGEMENT Holding S.A.	759,887	$17.20M	0.0%	-14.4%	1.600%
11/4/2024	Crossmark Global Holdings Inc.	11,367	$0.26M	0.0%	N/A	0.024%
11/1/2024	Assetmark Inc.	1,519	$34K	0.0%	N/A	0.003%
10/31/2024	Principal Financial Group Inc.	443,141	$10.03M	0.0%	N/A	1.036%
10/30/2024	AlphaCentric Advisors LLC	37,500	$0.85M	0.6%	-37.5%	0.088%
10/29/2024	Harbor Capital Advisors Inc.	133,707	$3.03M	0.1%	+141.8%	0.313%
10/25/2024	China Universal Asset Management Co. Ltd.	7,138	$0.16M	0.0%	+69.1%	0.017%
10/10/2024	Exchange Traded Concepts LLC	6,707	$0.15M	0.0%	-29.2%	0.016%
10/7/2024	GAMMA Investing LLC	2,026	$46K	0.0%	+105.1%	0.005%
10/5/2024	Handelsbanken Fonder AB	218,700	$4.95M	0.0%	+2.4%	0.511%
8/19/2024	Point72 Asset Management L.P.	58,500	$1.18M	0.0%	-82.9%	0.137%
8/16/2024	Perceptive Advisors LLC	572,000	$11.58M	0.3%	N/A	1.337%
8/15/2024	The Manufacturers Life Insurance Company	97,392	$1.97M	0.0%	+275.2%	0.228%
8/15/2024	Armistice Capital LLC	1,972,000	$39.91M	0.5%	+17.9%	4.610%
8/14/2024	Cubist Systematic Strategies LLC	96,409	$1.95M	0.0%	+923.5%	0.203%
8/14/2024	First Light Asset Management LLC	1,384,768	$28.03M	2.5%	+16.1%	3.237%
8/14/2024	Marshall Wace LLP	88,987	$1.80M	0.0%	N/A	0.208%
8/14/2024	Avoro Capital Advisors LLC	700,000	$14.17M	0.2%	N/A	1.636%
8/14/2024	HighVista Strategies LLC	127,255	$2.58M	0.9%	-19.6%	0.297%
8/12/2024	XTX Topco Ltd	10,177	$0.21M	0.0%	N/A	0.024%
8/10/2024	L & S Advisors Inc	58,335	$1.18M	0.1%	+16.1%	0.136%
8/9/2024	Renaissance Technologies LLC	326,800	$6.61M	0.0%	+97.2%	0.764%
8/6/2024	Candriam S.C.A.	759,180	$15.37M	0.1%	-14.6%	1.775%
8/3/2024	TD Asset Management Inc	97,186	$1.97M	0.0%	+76.7%	0.227%
8/1/2024	Natixis Advisors LLC	12,912	$0.26M	0.0%	N/A	0.030%
7/30/2024	Pinnacle Associates Ltd.	242,001	$4.90M	0.1%	+202.2%	0.566%
7/30/2024	BNP PARIBAS ASSET MANAGEMENT Holding S.A.	888,081	$17.98M	0.0%	+0.6%	2.076%
7/9/2024	Harbor Capital Advisors Inc.	55,289	$1.12M	0.1%	+27.2%	0.129%
5/17/2024	Walleye Trading LLC	11,371	$0.28M	0.0%	-77.4%	0.027%
5/17/2024	Comerica Bank	78,770	$1.96M	0.0%	-3.8%	0.184%
5/16/2024	Kennedy Capital Management LLC	252,172	$6.28M	0.1%	-39.5%	0.589%
5/15/2024	Baker BROS. Advisors LP	4,942,823	$123.08M	1.5%	+176.1%	11.554%
5/15/2024	First Light Asset Management LLC	1,193,051	$29.71M	2.3%	-23.1%	2.789%
5/15/2024	Bellevue Group AG	12,500	$0.31M	0.0%	-37.5%	0.029%
5/15/2024	Price T Rowe Associates Inc. MD	401,646	$10M	0.0%	+45.1%	0.939%
5/15/2024	PEAK6 Investments LLC	9,000	$0.22M	0.0%	-40.0%	0.021%
5/14/2024	Platinum Investment Management Ltd.	333,001	$8.29M	0.3%	-8.0%	0.778%
5/10/2024	Westfield Capital Management Co. LP	1,038,917	$25.87M	0.1%	+13.3%	3.458%
5/10/2024	Tocqueville Asset Management L.P.	17,450	$0.44M	0.0%	-25.3%	0.058%
5/8/2024	BNP PARIBAS ASSET MANAGEMENT Holding S.A.	883,105	$21.99M	0.1%	+12.8%	2.940%
5/7/2024	Concurrent Investment Advisors LLC	21,799	$0.54M	0.0%	N/A	0.073%
5/2/2024	PDS Planning Inc	8,450	$0.21M	0.0%	N/A	0.028%
5/1/2024	BNP Paribas Financial Markets	8,834	$0.22M	0.0%	-76.0%	0.029%
4/29/2024	China Universal Asset Management Co. Ltd.	6,859	$0.17M	0.0%	+71.4%	0.016%
4/26/2024	Pinnacle Associates Ltd.	80,090	$1.99M	0.0%	N/A	0.267%
4/23/2024	Fishman Jay A Ltd. MI	9,000	$0.22M	0.0%	-73.9%	0.030%
4/9/2024	Woodstock Corp	24,981	$0.62M	0.1%	+16.3%	0.083%
3/22/2024	PNC Financial Services Group Inc.	7,560	$0.14M	0.0%	N/A	0.025%
2/15/2024	Parkman Healthcare Partners LLC	312,889	$5.66M	0.8%	+155.0%	1.042%
2/15/2024	Comerica Bank	81,850	$1.48M	0.0%	+18,088.9%	0.272%
2/14/2024	First Light Asset Management LLC	1,550,471	$28.03M	2.3%	-25.1%	5.161%
2/14/2024	Bellevue Group AG	20,000	$0.36M	0.0%	-49.0%	0.067%
2/14/2024	Verition Fund Management LLC	740,539	$13.39M	0.1%	-19.2%	2.465%
2/14/2024	Platinum Investment Management Ltd.	362,080	$6.55M	0.3%	+26.8%	1.205%
2/13/2024	Tower Research Capital LLC TRC	2,328	$42K	0.0%	-76.4%	0.008%
2/13/2024	Armistice Capital LLC	1,536,000	$27.77M	0.4%	+53.6%	5.113%
2/9/2024	Westfield Capital Management Co. LP	917,304	$16.59M	0.1%	N/A	3.054%
2/9/2024	Trexquant Investment LP	196,323	$3.55M	0.1%	+177.6%	0.654%
2/7/2024	Jump Financial LLC	77,332	$1.40M	0.0%	+108.6%	0.257%
2/7/2024	BNP Paribas Financial Markets	36,851	$0.67M	0.0%	+10,489.4%	0.123%
2/5/2024	AtonRa Partners	10,435	$0.19M	0.4%	-9.9%	0.035%
2/1/2024	Handelsbanken Fonder AB	139,800	$2.53M	0.0%	+3.9%	0.465%
1/24/2024	Fishman Jay A Ltd. MI	34,500	$0.62M	0.1%	-8.0%	0.115%
1/24/2024	China Universal Asset Management Co. Ltd.	4,001	$72K	0.0%	+489.2%	0.013%
1/8/2024	Woodstock Corp	21,479	$0.39M	0.0%	+4.5%	0.071%
1/5/2024	Exchange Traded Concepts LLC	6,727	$0.12M	0.0%	+34.0%	0.022%
11/22/2023	Polar Capital Holdings Plc	1,011,500	$20.32M	0.1%	+33.2%	3.367%
11/15/2023	RA Capital Management L.P.	800,000	$16.07M	0.3%	N/A	2.663%
11/15/2023	Kennedy Capital Management LLC	156,705	$3.15M	0.1%	+27.2%	0.522%
11/15/2023	Armistice Capital LLC	1,000,000	$20.09M	0.3%	+14.2%	3.329%
11/14/2023	Braidwell LP	1,289,872	$25.91M	0.8%	N/A	4.294%
11/14/2023	Schonfeld Strategic Advisors LLC	52,100	$1.05M	0.0%	-21.2%	0.173%
11/14/2023	Deerfield Management Company L.P. Series C	448,753	$9.02M	0.2%	N/A	1.494%
11/14/2023	Trexquant Investment LP	70,719	$1.42M	0.0%	N/A	0.235%
11/13/2023	Fishman Jay A Ltd. MI	37,500	$0.75M	0.1%	+82.9%	0.125%
11/13/2023	FMR LLC	266,347	$5.35M	0.0%	-7.2%	0.887%
11/13/2023	Maven Securities LTD	22,500	$0.45M	0.0%	N/A	0.075%
11/9/2023	Deutsche Bank AG	96,370	$1.94M	0.0%	+1,051.4%	0.321%
11/7/2023	Alpha DNA Investment Management LLC	27,957	$0.56M	0.2%	N/A	0.093%
11/7/2023	Jump Financial LLC	37,067	$0.75M	0.0%	+104.1%	0.123%
11/3/2023	Platinum Investment Management Ltd.	285,479	$5.74M	0.2%	N/A	0.950%
10/27/2023	TD Asset Management Inc	81,786	$1.64M	0.0%	+246.8%	0.272%
10/25/2023	BluePath Capital Management LLC	1,534	$31K	0.0%	N/A	0.005%
10/25/2023	AtonRa Partners	11,588	$0.23M	0.5%	-18.5%	0.039%

Data available starting January 2016

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Today's Range

Now: $14.68

$14.64

$15.30

50 Day Range

MA: $21.83

$13.81

$27.51

52 Week Range

Now: $14.68

$12.17

$28.67

Volume

346,432 shs

Average Volume

404,265 shs

Market Capitalization

$1.01 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

Who are the company insiders with the largest holdings of Bicycle Therapeutics?: Bicycle Therapeutics' top insider investors include:
Bros Advisors Lp Baker (Director)
Kevin Lee (CEO)
Michael Skynner (CTO)
Nicholas Keen (Insider)
Nigel Crockett (Insider)
Alistair Milnes (COO)
Lee Kalowski (CFO)
Travis Alvin Thompson (CAO)
Michael Charles Ferguso Hannay (Insider)
Learn More about top insider investors at Bicycle Therapeutics.
Who are the major institutional investors of Bicycle Therapeutics?: Bicycle Therapeutics' top institutional investors include:
Westfield Capital Management Co. LP — 3.90%
Tybourne Capital Management HK Ltd. — 2.93%
Point72 Asset Management L.P. — 1.89%
BNP PARIBAS ASSET MANAGEMENT Holding S.A. — 1.60%
Parkman Healthcare Partners LLC — 0.94%
Principal Financial Group Inc. — 1.04%
Learn More about top institutional investors of Bicycle Therapeutics stock.
Which major investors are selling Bicycle Therapeutics stock?: During the last quarter, BCYC stock was sold by these institutional investors:
BNP PARIBAS ASSET MANAGEMENT Holding S.A.
Tybourne Capital Management HK Ltd.
Parkman Healthcare Partners LLC
Verition Fund Management LLC
AlphaCentric Advisors LLC
Wexford Capital LP
Exchange Traded Concepts LLC
Horizon Kinetics Asset Management LLC
During the previous year, company insiders that have sold Bicycle Therapeutics company stock include:
Bros Advisors Lp Baker (Director)
Kevin Lee (CEO)
Michael Skynner (CTO)
Nicholas Keen (Insider)
Nigel Crockett (Insider)
Alistair Milnes (COO)
Learn More investors selling Bicycle Therapeutics stock.
Which major investors are buying Bicycle Therapeutics stock?: During the previous quarter, BCYC stock was acquired by institutional investors including:
Point72 Asset Management L.P.
Principal Financial Group Inc.
Principal Financial Group Inc.
Westfield Capital Management Co. LP
FMR LLC
Harbor Capital Advisors Inc.
State Street Corp
The Manufacturers Life Insurance Company